FINANCIAL DATA (IFRS)

1st QuarterFiscal Year Ending March 31, 2021

[2021年3⽉期第1四半期]April 1, 2020 – June 30, 2020

⽬次　CONTENTS

連結決算概要／Financial Summary　(Consolidated) 1連結財政状態計算書／Consolidated statement of financial position 3連結損益計算書／Consolidated statement of income 5連結キャッシュ・フロー計算書／Consolidated statement of cash flows 6地域別・事業別・品⽬別売上⾼／Net Sales by Destination,Business and Product type 8地域別・事業別売上⾼／Net Sales by Destination and Business 9地域別・品⽬別売上⾼／Net Sales by Destination and Product type 12所在地別売上⾼および営業利益の状況／Net Sales and Operating Income (Loss) by Geographical Region 13

関連データ／Associated Data 14会社概要／Corporate Data 15

補⾜事項　Notes

2018年3⽉期第3四半期にシスメックス・ビオメリュー株式会社の合弁を解消しました。In the third quarter of the fiscal year ended March 31, 2018, the joint venture Sysmex bioMérieux Co., Ltd., was dissolved.

2018年3⽉期第1四半期にオックスフォード ジーン テクノロジー アイピー リミテッドを⼦会社化しました。In the first quarter of the fiscal year ended March 31, 2018, Oxford Gene Technology IP Limited became a subsidiary.

2018年3⽉期第1四半期にシスメックス タイワン カンパニー リミテッドによる直接販売・直接サービスを開始しました。In the first quarter of the fiscal year ended March 31, 2018, Sysmex Taiwan Co., Ltd., commenced direct sales and service.

2017年3⽉期第1四半期に株式会社理研ジェネシスを⼦会社化しました。In the first quarter of the fiscal year ended March 31, 2017, RIKEN GENESIS Co., Ltd., became a subsidiary.

2017年3⽉期よりIFRSを適⽤し、2017年3⽉期第1四半期からIFRSに基づき開⽰しています。From fiscal year ended March 31, 2017, Sysmex adopts IFRS and disclose financial information based on IFRS from the first three months of the fiscal year ended March 31, 2017.

注意事項　Cautionary Notes

本資料のうち、業績⾒通し等に記載されている各数値は、現在⼊⼿可能な情報による判断および仮定に基づき算出しており、判断や仮定に内在する不確定性および今後の事業運営や内外の状況変化により、実際の業績等が⾒通しの数値と⼤きく異なる可能性があります。This material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysmex Group). These forward-looking statements are based on current judgments and assumptions of the Sysmex Group

in light of the information currently available to it, and involve known and unknown risks, uncertainties and other factors, including but not limited to: global economic conditions, competitive situations and changes in exchange rates.

Such risks, uncertainties and other factors may cause our actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed

or implied by these forward-looking statements.

連結決算概要　Financial Summary (Consolidated)（百万円）（JPY million）

売上⾼ Net sales 59,167 61,719 65,961 68,540 60,511売上原価 Cost of sales 24,752 26,848 28,322 31,670 29,887売上総利益 Gross profit 34,414 34,870 37,638 36,869 30,624販売費及び⼀般管理費 Selling, general and administrative expenses 17,236 18,895 20,131 20,706 18,928研究開発費 Research and development expenses 3,831 3,658 4,207 4,995 4,915その他の営業損益 Other operating income (expenses) 530 115 531 112 176営業利益 Operating profit 13,877 12,432 13,831 11,279 6,957当期利益 Profit 9,439 8,126 9,375 6,620 4,442親会社の所有者に帰属する当期利益 Profit attributable to owners of the parent 9,449 8,220 9,424 6,697 4,487希薄化後1株当たり当期利益（円） Diluted earnings per share(￥) 45.28 39.39 45.10 32.05 21.46親会社所有者帰属持分当期利益率 Return on equity［ROE］ - - - - -売上総利益率 Gross profit per net sales 58.2 56.5 57.1 53.8 50.6売上⾼営業利益率 Operating profit to net sales 23.5 20.1 21.0 16.5 11.5売上⾼当期利益率 Profit attributable to owners of the parent to net sales 16.0 13.3 14.3 9.8 7.3売上⾼研究開発費率 R&D expenditure per net sales 6.5 5.9 6.4 7.3 8.1

資本⾦ Capital stock 11,611 12,276 12,654 12,877 12,965⾃⼰株式控除後期末株式数（千株） Number of outstanding stock excluding treasury stock (thousand shares) 208,186.4 208,518.9 208,708.2 208,819.7 208,863.7資本合計 Total equity 210,252 241,443 265,182 278,347 276,302資産合計 Total assets 279,817 321,979 346,775 389,291 368,826親会社所有者帰属持分⽐率 Equity attributable to owners of the parent to total assets 74.8 74.8 76.3 71.3 74.7１株当たり親会社所有者帰属持分(円） Equity attributable to owners of the parent per share（￥） 1,005.86 1,154.57 1,267.07 1,329.78 1,319.22

営業活動によるキャッシュ・フロー Net cash provided by (used in) operating activities 702 9,838 3,296 7,736 9,904投資活動によるキャッシュ・フロー Net cash provided by (used in) investment activities △ 6,493 △ 16,079 △ 5,892 △ 566 △ 8,619財務活動によるキャッシュ・フロー Net cash provided by (used in) financing activities △ 5,475 △ 6,220 △ 7,326 △ 8,878 △ 9,085現⾦及び現⾦同等物の期末残⾼ Cash and cash equivalents at the end of the term 42,598 46,048 51,144 48,368 48,734

設備投資の状況　Capital Expenditure

項⽬ Item設備投資（有形） Capital expenditure (tangible) 2,225 1,978 2,562 3,140 1,634減価償却費及び償却費 Depreciation and amortization 3,280 3,481 3,803 5,761 6,198

2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q 2021.3 1Q

決算期 Fiscal Term2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q 2021.3 1Q

項⽬ Item

2021.3 1Q 項⽬ Item

決算期 Fiscal Term2017.3 F.Y. 2018.3 F.Y. 2019.3 FY 2020.3 FY 2021.3 1Q

項⽬ Item

決算期 Fiscal Term2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q

1

換算レート（通期実績）　Average Exchange Rate (Annual)

USドル USD （円） (JPY) 108.4 110.9 110.9 108.7ユーロ EUR （円） (JPY) 118.8 129.7 128.4 120.8元 CNY （円） (JPY) 16.1 16.8 16.5 15.6

換算レート（期中平均）　Average Exchange Rate (Periods)

USドル USD （円） (JPY) 108.1 111.1 109.1 109.9 107.6ユーロ EUR （円） (JPY) 122.0 122.2 130.1 123.5 118.5元 CNY （円） (JPY) 16.5 16.2 17.1 16.1 15.2

決算期 Fiscal Term2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q 2021.3 1Q

項⽬ Item

決算期 Fiscal Term2017.3 F.Y. 2018.3 F.Y. 2019.3 F.Y. 2020.3 F.Y.

2

連結財政状態計算書　Consolidated statement of financial position

資産　Assets （百万円）（構成⽐︓%）（JPY million）(Ratio︓%)

増減Ratio Ratio Ratio Ratio Ratio (Variance)

Current assets現⾦及び現⾦同等物 Cash and cash equivalents 57,944 20.7 61,444 19.1 51,062 14.7 56,592 14.5 48,734 13.2 △7,858営業債権及びその他の債権 Trade and other receivables 63,084 22.5 72,567 22.5 84,247 24.3 85,650 22.0 71,743 19.5 △13,907棚卸資産 Inventories 36,998 13.2 40,975 12.7 40,231 11.6 48,303 12.4 53,431 14.5 5,128その他の短期⾦融資産 Other short-term financial assets 528 0.2 214 0.1 7,644 2.2 421 0.1 857 0.2 436未収法⼈所得税 Income taxes receivable 457 0.2 619 0.2 412 0.1 546 0.1 561 0.2 15その他の流動資産 Other current assets 7,303 2.6 9,131 2.8 11,824 3.4 14,191 3.6 10,321 2.8 △3,870

流動資産合計 Total current assets 166,318 59.4 184,952 57.4 195,423 56.4 205,704 52.8 185,649 50.3 △20,055⾮流動資産 Non-current assets

有形固定資産 Property, plant and equipment 60,144 21.5 67,651 21.0 76,312 22.0 96,839 24.9 95,399 25.9 △1,440のれん Goodwill 8,308 3.0 12,251 3.8 11,917 3.4 11,271 2.9 11,310 3.1 39無形資産 Intangible assets 21,228 7.6 29,765 9.2 33,037 9.5 39,543 10.2 40,131 10.9 588持分法で会計処理されている投資 Investments accounted for using the equity method 552 0.2 411 0.1 634 0.2 2,945 0.8 2,517 0.7 △428営業債権及びその他の債権 Trade and other receivables 8,813 3.1 10,882 3.4 12,202 3.5 12,845 3.3 12,866 3.5 21その他の⻑期⾦融資産 Other long-term financial assets 6,107 2.2 7,486 2.3 7,050 2.0 6,192 1.6 6,259 1.7 67退職給付に係る資産 Asset for retirement benefits 666 0.2 802 0.2 917 0.3 897 0.2 904 0.2 7その他の⾮流動資産 Other non-current assets 2,095 0.7 2,343 0.7 3,456 1.0 5,810 1.5 6,640 1.8 830繰延税⾦資産 Deferred tax assets 5,581 2.0 5,432 1.7 5,823 1.7 7,240 1.9 7,145 1.9 △95

⾮流動資産合計 Total non-current assets 113,499 40.6 137,027 42.6 151,352 43.6 183,586 47.2 183,177 49.7 △409Total assets 279,817 100.0 321,979 100.0 346,775 100.0 389,291 100.0 368,826 100.0 △20,465

項⽬ Item流動資産

資産合計

2017.3 F.Y. 2018.3 F.Y. 2019.3 FY 2020.3 FY 2021.3 1Q

3

負債および資本　Liabilities and Equity （百万円）（構成⽐︓%）（JPY million）(Ratio︓%)

増減

Ratio Ratio Ratio Ratio Ratio (Variance)負債 Liabilities

流動負債 Current liabilities営業債務及びその他の債務 Trade and other payables 24,376 8.7 28,579 8.9 29,778 8.6 33,917 8.7 25,841 7.0 △8,076リース負債 Lease liabilities - - - - - - 5,701 1.5 5,546 1.5 △155その他の短期⾦融負債 Other short-term financial liabilities 956 0.3 690 0.2 806 0.2 552 0.1 843 0.2 291未払法⼈所得税 Income taxes payable 2,915 1.0 7,717 2.4 6,947 2.0 5,673 1.5 2,333 0.6 △3,340引当⾦ Provisions 610 0.2 614 0.2 693 0.2 751 0.2 738 0.2 △13契約負債 Contract Liabilities - - - - 9,303 2.7 12,001 3.1 9,914 2.7 △2,087前受⾦ Advances received 6,418 2.3 4,588 1.4 - - - - - - -未払費⽤ Accrued expenses 8,330 3.0 10,632 3.3 10,791 3.1 12,508 3.2 10,509 2.8 △1,999未払賞与 Accrued bonuses 6,636 2.4 7,474 2.3 7,670 2.2 7,591 1.9 4,619 1.3 △2,972その他の流動負債 Other current liabilities 9,708 3.5 10,501 3.3 5,257 1.5 5,448 1.4 6,164 1.7 716

流動負債合計 Total current liabilities 59,952 21.4 70,796 22.0 71,247 20.5 84,145 21.6 66,512 18.0 △17,633⾮流動負債 Non-current liabilities

リース負債 Lease liabilities - - - - - - 16,935 4.4 16,390 4.4 -その他の⻑期⾦融負債 Other long-term financial liabilities 549 0.2 712 0.2 415 0.1 269 0.1 19 0.0 △250退職給付に係る負債 Liability for retirement benefits 654 0.2 731 0.2 857 0.2 925 0.2 990 0.3 65引当⾦ Provisions 2,318 0.8 202 0.1 226 0.1 255 0.1 259 0.1 4その他の⾮流動負債 Other non-current liabilities 3,527 1.3 2,652 0.8 3,203 0.9 2,061 0.5 2,178 0.6 117繰延税⾦負債 Deferred tax liabilities 2,562 0.9 5,439 1.7 5,642 1.6 6,351 1.6 6,172 1.7 △179

⾮流動負債合計 Total non-current liabilities 9,612 3.4 9,739 3.0 10,345 3.0 26,798 6.9 26,011 7.1 △787負債合計 Total Liabilities 69,564 24.9 80,536 25.0 81,592 23.5 110,944 28.5 92,523 25.1 △18,421資本 Equity

親会社の所有者に帰属する持分 Equity attributable to owners of the parent資本⾦ Capital stock 11,611 4.1 12,276 3.8 12,654 3.6 12,877 3.3 12,965 3.5 88資本剰余⾦ Capital surplus 17,303 6.2 17,664 5.5 17,876 5.2 18,487 4.7 18,766 5.1 279利益剰余⾦ Retained earnings 188,506 67.4 214,952 66.8 241,445 69.6 261,321 67.1 258,291 70.0 △3,030⾃⼰株式 Treasury stock △289 △0.1 △295 △0.1 △302 △0.1 △306 △0.1 △306 △0.1 △0その他の資本の構成要素 Other components of equity △7,725 △2.8 △3,847 △1.2 △7,225 △2.1 △14,697 △3.8 △14,180 △3.8 517

親会社の所有者に帰属する持分合計 Total equity attributable to owners of the parent 209,406 74.8 240,749 74.8 264,448 76.3 277,683 71.3 275,536 74.7 △2,147⾮⽀配持分 Non-controlling interests 845 0.3 693 0.2 733 0.2 663 0.2 765 0.2 102

資本合計 Total equity 210,252 75.1 241,443 75.0 265,182 76.5 278,347 71.5 276,302 74.9 △2,045負債及び資本合計 Total liabilities and equity 279,817 100.0 321,979 100.0 346,775 100.0 389,291 100.0 368,826 100.0 △20,465

項⽬ Item

決算期 Fiscal Term 2017.3 F.Y. 2018.3 F.Y. 2019.3 FY 2020.3 FY 2021.3 1Q

4

連結損益計算書　Consolidated statement of income（百万円）（構成⽐︓%）（JPY million）(Ratio︓%)

項⽬ Item Ratio Ratio Ratio Ratio Ratio売上⾼ Net sales 59,167 100.0 61,719 100.0 65,961 100.0 68,540 100.0 60,511 100.0売上原価 Cost of sales 24,752 41.8 26,848 43.5 28,322 42.9 31,670 46.2 29,887 49.4売上総利益 Gross profit 34,414 58.2 34,870 56.5 37,638 57.1 36,869 53.8 30,624 50.6販売費及び⼀般管理費 Selling, general and administrative expenses 17,236 29.1 18,895 30.6 20,131 30.5 20,706 30.2 18,928 31.3研究開発費 Research and development expenses 3,831 6.5 3,658 5.9 4,207 6.4 4,995 7.3 4,915 8.1その他の営業収益 Other operating income 606 1.0 141 0.2 614 0.9 213 0.3 305 0.5その他の営業費⽤ Other operating expenses 75 0.1 25 - 83 0.1 101 0.1 128 0.2営業利益 Operating profit 13,877 23.5 12,432 20.1 13,831 21.0 11,279 16.5 6,957 11.5⾦融収益 Financial income 210 0.4 71 0.1 93 0.1 97 0.1 82 0.1⾦融費⽤ Financial expenses 28 0.0 24 0.0 251 0.4 234 0.3 221 0.4持分法による投資損益 Share of profit (loss) of associates accounted for using the equity method △155 △0.3 △128 △0.2 △320 △0.5 △414 △0.6 △427 △0.7関連会社株式売却益 Gain on sales of investment in associates - - - - - - - - - -為替差損益 Foreign exchange gain (loss) △1,597 △2.7 △409 △0.7 △586 △0.9 △1,065 △1.6 90 0.1税引前当期利益 Profit before tax 12,307 20.8 11,940 19.3 12,766 19.4 9,661 14.1 6,481 10.7法⼈所得税費⽤ Income taxes expenses 2,868 4.8 3,813 6.2 3,390 5.1 3,041 4.4 2,038 3.4当期利益 Profit 9,439 16.0 8,126 13.2 9,375 14.2 6,620 9.7 4,442 7.3

当期利益の帰属 Profit attributable to親会社の所有者 Owners of the parent 9,449 16.0 8,220 13.3 9,424 14.3 6,697 9.8 4,487 7.4⾮⽀配持分 Non-controlling interests △10 0.0 △93 △0.2 △49 △0.1 △76 △0.1 △44 △0.1当期利益 Profit 9,439 16.0 8,126 13.2 9,375 14.2 6,620 9.7 4,442 7.3

1株当たり当期利益 Earnings per share基本的1株当たり当期利益 Basic 45.44 - 39.48 - 45.19 - 32.09 - 21.49 -希薄化後1株当たり当期利益 Diluted 45.28 - 39.39 - 45.10 - 32.05 - 21.46 -

2021.3 1Q決算期 Fiscal Term 2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q

5

連結キャッシュ・フロー計算書　Consolidated statement of cash flows（百万円）（JPY million）

項⽬ Item営業活動によるキャッシュ・フロー Cash flows from operating activities

税引前当期利益 Profit before tax 12,307 11,940 12,766 9,661 6,481減価償却費及び償却費 Depreciation and amortization 3,280 3,481 3,803 5,761 6,198関連会社株式売却益 Gain on sales of investment in associates - - - - -営業債権の増減額 Decrease (increase) in trade receivable 1,485 3,894 3,476 4,589 13,916棚卸資産の増減額 Decrease (increase) in inventories △1,704 △3,463 △1,852 △3,638 △4,461営業債務の増減額 Increase (decrease) in trade payable △1,683 688 △3,435 △2,128 △4,148未払⼜は未収消費税等の増減額 Incrrease(Decrease) in consumption taxes receivable and payable 2,445 1,659 1,557 2,942 3,366前受⾦の増減額 Increase (decrease) in advances received △4,461 △609 - - -契約負債の増減額 Increase (decrease) in contract liabilities - - △1,094 36 △2,062未払賞与の増減額 Increase (decrease) in accrued bonuses △3,435 △3,198 △3,628 △3,847 △2,974その他 Other △609 △1,534 △922 2,011 △818

⼩計 Subtotal 7,624 12,857 10,670 15,387 15,496利息及び配当⾦の受取額 Interest and dividend received 197 68 85 75 72利息の⽀払額 Interest paid △24 △14 △9 △194 △195法⼈所得税の⽀払額 Income taxes paid △7,094 △3,072 △7,449 △7,532 △5,469

営業活動によるキャッシュ・フロー Net cash provided by (used in) operating activities 702 9,838 3,296 7,736 9,904

決算期 Fiscal Term2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q 2021.3 1Q

6

（百万円）（JPY million）

項⽬ Item投資活動によるキャッシュ・フロー Cash flows from investing activities

有形固定資産の取得による⽀出 Purchases of property, plant and equipment △3,194 △3,119 △2,819 △3,257 △1,915無形資産の取得による⽀出 Purchases of intangible assets △1,300 △1,640 △1,771 △2,374 △4,625⻑期前払費⽤の増加を伴う⽀出 Payments resulting in an increase in long-term prepaid expenses - - - △379 △1,170資本性⾦融商品の取得による⽀出 Purchases of investments in equity instruments △629 △1,706 △1,007 △1,506 -資本性⾦融商品の売却による収⼊ Proceeds from sales of investments in equity instruments - - - - -⼦会社⼜はその他の事業の取得による⽀出 Acquisitions of subsidiaries or other businesses △1,453 △9,469 △20 - -短期貸付⾦の純増減額 Net decrease (increase) in short-term loans receivable - - - - -定期預⾦の預⼊による⽀出 Payments into time deposits - - - △174 △598定期預⾦の払戻による収⼊ Proceeds from withdrawals of time deposits - - - 7,187 -その他 Other 84 △144 △273 △60 △309

　投資活動によるキャッシュ・フロー Net cash provided by (used in) investing activities △6,493 △16,079 △5,892 △566 △8,619財務活動によるキャッシュ・フロー Cash flows from financing activities

配当⾦の⽀払額 Dividends paid △5,820 △6,245 △7,506 △7,513 △7,517リース負債の返済による⽀払額 Repayments of lease liabilities - - - △1,440 △1,704その他 Other 345 24 180 75 136

　財務活動によるキャッシュ・フロー Net cash provided by (used in) financing activities △5,475 △6,220 △7,326 △8,878 △9,085現⾦及び現⾦同等物に係る換算差額 Effects of exchange rate changes on cash and cash equivalents △2,617 566 △378 △985 △57現⾦及び現⾦同等物の純増減額 Net increase (decrease) in cash and cash equivalents △13,883 △11,895 △10,300 △2,693 △7,857現⾦及び現⾦同等物の期⾸残⾼ Cash and cash equivalents at the beginning of the term 56,481 57,944 61,444 51,062 56,592現⾦及び現⾦同等物の期末残⾼ Cash and cash equivalents at the end of the term 42,598 46,048 51,144 48,368 48,734

2021.3 1Q決算期 Fiscal Term

2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q

7

地域別・事業別・品⽬別売上⾼　Net Sales by Destination, Business and Product type

地域別売上⾼　Net Sales by Destination （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)決算期 Fiscal Term

地域 Destination Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O YJapan 9,201 15.6 118.2 9,394 15.2 102.1 9,562 14.5 101.8 10,140 14.8 106.0 9,380 15.5 92.5　Americas 13,361 22.6 99.1 14,334 23.2 107.3 14,946 22.7 104.3 15,808 23.1 105.8 13,975 23.1 88.4　EMEA 17,267 29.2 98.2 16,737 27.1 96.9 18,196 27.6 108.7 19,200 28.0 105.5 18,214 30.1 94.9　China 14,461 24.4 98.0 16,174 26.2 111.8 17,885 27.1 110.6 17,679 25.9 98.8 13,843 22.9 78.3　Asia-Pacific 4,875 8.2 121.0 5,078 8.3 104.2 5,370 8.2 105.8 5,710 8.3 106.3 5,096 8.4 89.2Overseas Total 49,965 84.4 100.2 52,325 84.8 104.7 56,398 85.5 107.8 58,399 85.2 103.5 51,130 84.5 87.6Total Sales 59,167 100.0 102.6 61,719 100.0 104.3 65,961 100.0 106.9 68,540 100.0 103.9 60,511 100.0 88.3

●EMEA︓欧州、中東、アフリカ地域 ●EMEA: Europe, the Middle East and Africa

事業別売上⾼　Net Sales by Business （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)決算期 Fiscal Term

事業 Business Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y ⾎球計数検査 　Hematology 37,358 63.1 101.5 39,199 63.5 104.9 41,378 62.7 105.6 43,167 63.0 104.3 37,325 61.7 86.5 ⾎液凝固検査 　Hemostasis 10,354 17.5 104.2 9,388 15.2 90.7 10,604 16.1 112.9 11,036 16.1 104.1 11,387 18.8 103.2 尿検査 　Urinalysis 3,809 6.4 85.6 5,211 8.4 136.8 4,803 7.3 92.2 4,922 7.2 102.5 3,522 5.8 71.6 免疫検査 　Immunochemistry 1,804 3.1 198.5 2,257 3.7 125.1 3,054 4.6 135.3 2,981 4.3 97.6 2,542 4.2 85.3 ⽣化学検査 　Clinical Chemistry 868 1.5 105.5 680 1.1 78.4 720 1.1 105.9 621 0.9 86.2 612 1.0 98.6 FCM事業 FCM Business 598 1.0 96.1 420 0.7 70.3 288 0.4 68.7 373 0.5 129.4 183 0.3 49.2 IVDその他　※ 　Other IVD Business 3,252 5.5 110.1 3,449 5.6 106.1 2,785 4.2 80.7 2,940 4.3 105.6 2,487 4.1 84.6IVD事業 IVD Business 58,047 98.1 102.7 60,608 98.2 104.4 63,635 96.5 105.0 66,044 96.4 103.8 58,062 96.0 87.9LS事業　※ Life Science Business 1,119 1.9 99.6 1,111 1.8 99.2 2,325 3.5 209.2 2,495 3.6 107.3 2,449 4.0 98.1その他 Other Business - - - - - - - - - - - - 0 0.0 -合　　計 Total Sales 59,167 100.0 102.6 61,719 100.0 104.3 65,961 100.0 106.9 68,540 100.0 103.9 60,511 100.0 88.3※ 臨床検査情報システム、仕⼊れ商品等の売上は「その他」に含めておりましたが、2020年3⽉期以降は、「IVDその他」「LS事業」に分割して表⽰しております。※ “Clinical laboratory information systems” and “sales of third-party products, others” which were previously classified under “Other Business” will be classified separately as “Other IVD Business” and the “Life Science Business” from the fiscal year ended March 31, 2020.

品⽬別売上⾼　Net Sales by Product Type （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)

Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y機器 Instrument 19,573 33.1 108.2 18,470 29.9 94.4 16,410 24.9 88.8 16,718 24.4 101.9 16,708 27.6 99.9試薬 Reagent 30,878 52.2 100.9 33,781 54.7 109.4 40,147 60.9 118.8 40,638 59.3 101.2 32,909 54.4 81.0サービス Service 6,656 11.3 92.4 7,260 11.8 109.1 7,598 11.5 104.7 8,660 12.6 114.0 8,624 14.3 99.6その他 Others 2,058 3.5 118.0 2,206 3.6 107.2 1,804 2.7 81.8 2,521 3.7 139.7 2,269 3.7 90.0合計 Total Sales 59,167 100.0 102.6 61,719 100.0 104.3 65,961 100.0 106.9 68,540 100.0 103.9 60,511 100.0 88.3※1 検査回数に応じて顧客に課⾦する取引について「その他」に含めておりましたが、2016年3⽉期以降「機器」「試薬」「サービス」に分割して表⽰しております。※1 Transactions involving customer billings according to the number of times tests were performed were previously included in “Other Businesses.” However, from the fiscal year ended March 31, 2016, these amounts are divided and presented in “Instrument,” “Reagent” and “Service.”

※2 中国地域において、2016年3⽉期までは消耗品を「試薬」に計上していましたが、2017年3⽉期より「その他」に組み替えております。※2 In China, sales of disposals have been adjusted in "Others" from the fiscal year ended in March 31, 2017 which was formally included in "Reagent."

※3 中国地域において、2019年3⽉期2Qまで「試薬」および「その他」に計上していた⼀部売上を、2019年3⽉期3Qより「サービス」に組み替えております。※3 In China, some sales previously included in “Reagent” and "Others" have been reclassified to “Service” from the third quarter of the fiscal year ended March 31, 2019.

2021.3 1Q

品⽬ Product Type

2018.3 1Q 2019.3 1Q 2020.3 1Q 2021.3 1Q

決算期 Fiscal Term 2017.3 1Q 2018.3 1Q

EMEA

2019.3 1Q 2020.3 1Q

中国ｱｼﾞｱ･ﾊﾟｼﾌｨｯｸ

海外 計合　　計

2017.3 1Q

2021.3 1Q

国　　内⽶州

2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q

※2※3

※1

8

地域別・事業別売上⾼　Net Sales by Destination and Business

⽇本　Japan （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)

事業 Business Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y ⾎球計数検査 　Hematology 4,053 44.1 117.4 4,000 42.6 98.7 4,072 42.6 101.8 4,177 41.2 102.6 3,984 42.5 95.4 ⾎液凝固検査 　Hemostasis 1,680 18.3 119.1 1,769 18.8 105.3 1,915 20.0 108.2 1,997 19.7 104.3 2,064 22.0 103.4 尿検査 　Urinalysis 535 5.8 119.2 587 6.3 109.9 690 7.2 117.5 699 6.9 101.2 609 6.5 87.1 免疫検査 　Immunochemistry 1,056 11.5 165.3 1,059 11.3 100.3 1,225 12.8 115.6 1,269 12.5 103.5 1,004 10.7 79.2 ⽣化学検査 　Clinical Chemistry 371 4.0 115.6 362 3.9 97.6 315 3.3 87.0 287 2.8 91.1 276 2.9 96.2 FCM事業 FCM Business 3 0.0 300.0 2 0.0 63.8 3 0.0 145.4 28 0.3 861.0 5 0.1 17.5 IVDその他　※ 　Other IVD Business 1,365 14.8 93.6 1,383 14.7 101.3 948 9.9 68.6 1,162 11.5 122.5 770 8.2 66.3IVD事業 IVD Business 9,066 98.5 117.2 9,165 97.6 101.1 9,172 95.9 100.1 9,621 94.9 104.9 8,714 92.9 90.6LS事業　※ Life Science Business 135 1.5 259.6 228 2.4 168.6 389 4.1 170.5 518 5.1 133.0 666 7.1 128.5その他 Other Business - - - - - - - - - - - - 0 0.0 -合　　計 Total Sales 9,201 100.0 118.2 9,394 100.0 102.1 9,562 100.0 101.8 10,140 100.0 106.0 9,380 100.0 92.5

海外　Overseas

事業 Business Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y ⾎球計数検査 　Hematology 33,304 66.7 99.8 35,198 67.3 105.7 37,305 66.1 106.0 38,989 66.8 104.5 33,341 65.2 85.5 ⾎液凝固検査 　Hemostasis 8,674 17.4 101.7 7,619 14.6 87.8 8,688 15.4 114.0 9,039 15.5 104.0 9,323 18.2 103.1 尿検査 　Urinalysis 3,274 6.6 81.9 4,623 8.8 141.2 4,112 7.3 88.9 4,223 7.2 102.7 2,913 5.7 69.0 免疫検査 　Immunochemistry 748 1.5 277.0 1,197 2.3 160.0 1,828 3.2 152.7 1,712 2.9 93.6 1,537 3.0 89.8 ⽣化学検査 　Clinical Chemistry 496 1.0 98.8 318 0.6 64.1 405 0.7 127.4 334 0.6 82.5 336 0.7 100.6 FCM事業 FCM Business 594 1.2 95.7 418 0.8 70.3 285 0.5 68.2 344 0.6 120.9 178 0.3 51.8 IVDその他　※ 　Other IVD Business 1,886 3.8 126.2 2,066 3.9 109.5 1,836 3.3 88.9 1,778 3.0 96.9 1,717 3.4 96.5IVD事業 IVD Business 48,980 98.0 100.4 51,442 98.3 105.0 54,463 96.6 105.9 56,422 96.6 103.6 49,348 96.5 87.5LS事業　※ Life Science Business 984 2.0 92.0 882 1.7 89.7 1,935 3.4 219.3 1,976 3.4 102.1 1,782 3.5 90.2その他 Other Business - - - - - - - - - - - - - - -合　　計 Total Sales 49,965 100.0 100.2 52,325 100.0 104.7 56,398 100.0 107.8 58,399 100.0 103.5 51,130 100.0 87.6※ 臨床検査情報システム、仕⼊れ商品等の売上は「その他」に含めておりましたが、2020年3⽉期以降は、「IVDその他」「LS事業」に分割して表⽰しております。※ “Clinical laboratory information systems” and “sales of third-party products, others” which were previously classified under “Other Business” will be classified separately as “Other IVD Business” and the “Life Science Business” from the fiscal year ended March 31, 2020.

2021.3 1Q

2021.3 1Q決算期 Fiscal Term 2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q

決算期 Fiscal Term 2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q

9

⽶州　Americas （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)

事業 Business Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y ⾎球計数検査 　Hematology 11,772 88.1 98.7 12,969 90.5 110.2 13,005 87.0 100.3 14,032 88.8 107.9 12,331 88.2 87.9 ⾎液凝固検査 　Hemostasis 885 6.6 121.7 564 3.9 63.7 848 5.7 150.3 756 4.8 89.2 937 6.7 123.9 尿検査 　Urinalysis 482 3.6 78.9 619 4.3 128.3 525 3.5 84.7 460 2.9 87.6 287 2.1 62.4 免疫検査 　Immunochemistry 10 0.1 - - - - 0 0.0 - 0 0.0 209.1 0 0.0 44.4 ⽣化学検査 　Clinical Chemistry - - - - - - - - - - - - - - - FCM事業 FCM Business 76 0.6 118.8 75 0.5 98.9 27 0.2 35.8 54 0.3 202.2 40 0.3 73.7 IVDその他　※ 　Other IVD Business 27 0.2 18.2 26 0.2 97.5 23 0.2 90.6 19 0.1 80.5 14 0.1 76.0IVD事業 IVD Business 13,255 99.2 98.3 14,255 99.4 107.5 14,430 96.5 101.2 15,323 96.9 106.2 13,611 97.4 88.8LS事業　※ Life Science Business 105 0.8 - 79 0.6 74.9 515 3.5 650.2 484 3.1 94.0 364 2.6 75.2その他 Other Business - - - - - - - - - - - - - - -合　　計 Total Sales 13,361 100.0 99.1 14,334 100.0 107.3 14,946 100.0 104.3 15,808 100.0 105.8 13,975 100.0 88.4

EMEA（欧州、中東、アフリカ地域 / Europe, the Middle East and Africa）

事業 Business Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y ⾎球計数検査 　Hematology 11,983 69.4 100.2 11,557 69.0 96.4 12,476 68.6 108.0 13,339 69.5 106.9 12,725 69.9 95.4 ⾎液凝固検査 　Hemostasis 1,747 10.1 91.3 1,453 8.7 83.2 1,494 8.2 102.8 1,637 8.5 109.6 1,703 9.4 104.0 尿検査 　Urinalysis 719 4.2 80.2 919 5.5 127.8 996 5.5 108.3 1,097 5.7 110.1 825 4.5 75.3 免疫検査 　Immunochemistry 19 0.1 - - - - 0 0.0 - 2 0.0 224.8 0 0.0 30.7 ⽣化学検査 　Clinical Chemistry 0 0.0 0.0 3 0.0 455.1 14 0.1 405.7 0 0.0 0.0 14 0.1 - FCM事業 FCM Business 448 2.6 92.8 206 1.2 46.1 187 1.0 90.4 217 1.1 116.4 80 0.4 37.1 IVDその他　※ 　Other IVD Business 1,470 8.5 122.0 1,794 10.7 122.1 1,639 9.0 91.3 1,438 7.5 87.8 1,490 8.2 103.6IVD事業 IVD Business 16,389 94.9 99.2 15,935 95.2 97.2 16,809 92.4 105.5 17,733 92.4 105.5 16,841 92.5 95.0LS事業　※ Life Science Business 877 5.1 82.2 802 4.8 91.4 1,387 7.6 172.9 1,467 7.6 105.8 1,372 7.5 93.5その他 Other Business - - - - - - - - - - - - - - -合　　計 Total Sales 17,267 100.0 98.2 16,737 100.0 96.9 18,196 100.0 108.7 19,200 100.0 105.5 18,214 100.0 94.9※ 臨床検査情報システム、仕⼊れ商品等の売上は「その他」に含めておりましたが、2020年3⽉期以降は、「IVDその他」「LS事業」に分割して表⽰しております。※ “Clinical laboratory information systems” and “sales of third-party products, others” which were previously classified under “Other Business” will be classified separately as “Other IVD Business” and the “Life Science Business” from the fiscal year ended March 31, 2020.

2019.3 1Q 2020.3 1Q 2021.3 1Q

決算期 Fiscal Term 2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q 2021.3 1Q

決算期 Fiscal Term 2017.3 1Q 2018.3 1Q

10

中国　China （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)

事業 Business Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y ⾎球計数検査 　Hematology 6,383 44.1 94.4 7,348 45.4 115.1 8,197 45.8 111.6 7,900 44.7 96.4 4,843 35.0 61.3 ⾎液凝固検査 　Hemostasis 5,345 37.0 102.3 4,812 29.8 90.0 5,605 31.3 116.5 5,871 33.2 104.7 5,979 43.2 101.8 尿検査 　Urinalysis 1,736 12.0 80.6 2,648 16.4 152.5 2,094 11.7 79.1 2,142 12.1 102.3 1,398 10.1 65.3 免疫検査 　Immunochemistry 699 4.8 264.8 1,153 7.1 165.0 1,754 9.8 152.0 1,571 8.9 89.6 1,432 10.3 91.1 ⽣化学検査 　Clinical Chemistry 280 1.9 84.1 167 1.0 59.7 205 1.2 123.1 167 0.9 81.4 116 0.8 69.6 FCM事業 FCM Business 16 0.1 145.5 42 0.3 255.7 4 0.0 9.6 17 0.1 421.9 37 0.3 213.9 IVDその他　※ 　Other IVD Business - - - 0 0.0 - 0 0.0 35.8 0 0.0 50.0 2 0.0 -IVD事業 IVD Business 14,461 100.0 98.0 16,174 100.0 111.8 17,862 99.9 110.4 17,670 99.9 98.9 13,809 99.8 78.2LS事業　※ Life Science Business - - - - - - 23 0.1 - 9 0.1 41.1 33 0.2 357.7その他 Other Business - - - - - - - - - - - - - - -合　　計 Total Sales 14,461 100.0 98.0 16,174 100.0 111.8 17,885 100.0 110.6 17,679 100.0 98.8 13,843 100.0 78.3

アジア・パシフィック　Asia-Pacific

事業 Business Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y ⾎球計数検査 　Hematology 3,165 64.9 116.8 3,324 65.5 105.0 3,625 67.5 109.1 3,716 65.1 102.5 3,440 67.5 92.6 ⾎液凝固検査 　Hemostasis 696 14.3 105.6 788 15.5 113.3 740 13.8 93.9 774 13.6 104.6 703 13.8 90.8 尿検査 　Urinalysis 336 6.9 99.7 435 8.6 129.7 496 9.3 114.0 523 9.2 105.4 401 7.9 76.7 免疫検査 　Immunochemistry 19 0.4 475.0 43 0.9 222.9 72 1.4 167.4 137 2.4 189.3 104 2.1 76.0 ⽣化学検査 　Clinical Chemistry 215 4.4 190.3 147 2.9 68.4 185 3.4 125.4 166 2.9 90.2 205 4.0 122.9 FCM事業 FCM Business 52 1.1 85.2 92 1.8 176.4 67 1.2 72.4 54 1.0 82.0 20 0.4 36.9 IVDその他　※ 　Other IVD Business 389 8.0 275.9 244 4.8 62.8 173 3.2 70.8 320 5.6 185.0 209 4.1 65.3IVD事業 IVD Business 4,874 100.0 121.0 5,077 100.0 104.1 5,361 99.8 105.6 5,695 99.7 106.2 5,085 99.8 89.3LS事業　※ Life Science Business 0 0.0 56.5 1 0.0 266.7 9 0.2 828.2 14 0.3 164.0 11 0.2 77.6その他 Other Business - - - - - - - - - - - - - - -合　　計 Total Sales 4,875 100.0 121.0 5,078 100.0 104.2 5,370 100.0 105.8 5,710 100.0 106.3 5,096 100.0 89.2※ 臨床検査情報システム、仕⼊れ商品等の売上は「その他」に含めておりましたが、2020年3⽉期以降は、「IVDその他」「LS事業」に分割して表⽰しております。※ “Clinical laboratory information systems” and “sales of third-party products, others” which were previously classified under “Other Business” will be classified separately as “Other IVD Business” and the “Life Science Business” from the fiscal year ended March 31, 2020.

2019.3 1Q 2020.3 1Q 2021.3 1Q

決算期 Fiscal Term 2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q 2021.3 1Q

決算期 Fiscal Term 2017.3 1Q 2018.3 1Q

11

地域別・品⽬別売上⾼　Net Sales by Destination and Product type （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)

地域 Destination/品⽬ Product Type Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y機器 Instrument 1,392 15.1 111.0 1,269 13.5 91.2 1,090 11.4 85.9 1,631 16.1 149.6 849 9.1 52.1試薬 Reagent 6,119 66.5 121.9 6,311 67.2 103.1 6,956 72.8 110.2 6,909 68.1 99.3 6,740 71.9 97.6

⽇本 サービス Service 1,100 12.0 112.7 1,196 12.7 108.7 1,136 11.9 95.0 1,193 11.8 105.0 1,373 14.6 115.1Japan その他 Others 589 6.4 109.9 617 6.6 104.8 377 4.0 61.1 405 4.0 107.4 418 4.5 103.2

合計 Total Sales 9,201 100.0 118.2 9,394 100.0 102.1 9,562 100.0 101.8 10,140 100.0 106.0 9,380 100.0 92.5機器 Instrument 4,358 32.6 101.8 4,372 30.5 100.3 4,041 27.0 92.4 4,096 25.9 101.4 3,793 27.1 92.6試薬 Reagent 5,439 40.7 98.1 6,063 42.3 111.5 6,827 45.7 112.6 7,327 46.4 107.3 5,998 42.9 81.9

⽶州 サービス Service 3,407 25.5 99.6 3,753 26.2 110.2 3,921 26.2 104.5 4,135 26.2 105.5 4,049 29.0 97.9Americas その他 Others 155 1.2 65.7 144 1.0 92.9 156 1.0 108.3 248 1.6 159.0 134 1.0 54.0

合計 Total Sales 13,361 100.0 99.1 14,334 100.0 107.3 14,946 100.0 104.3 15,808 100.0 105.8 13,975 100.0 88.4機器 Instrument 5,599 32.4 105.1 4,971 29.7 88.8 5,206 28.6 104.7 5,366 28.0 103.1 5,898 32.4 109.9試薬 Reagent 9,114 52.8 101.8 9,129 54.5 100.2 10,211 56.1 111.9 11,013 57.4 107.9 9,380 51.5 85.2

EMEA サービス Service 1,734 10.0 70.1 1,859 11.1 107.2 2,008 11.0 108.0 1,890 9.8 94.1 2,100 11.5 111.1その他 Others 818 4.7 98.4 777 4.6 95.0 769 4.2 99.0 930 4.8 120.9 834 4.6 89.7合計 Total Sales 17,267 100.0 98.2 16,737 100.0 96.9 18,196 100.0 108.7 19,200 100.0 105.5 18,214 100.0 94.9機器 Instrument 6,534 45.2 102.8 6,469 40.0 99.0 4,679 26.2 72.3 4,479 25.3 95.7 4,862 35.1 108.6試薬 Reagent 7,445 51.5 90.3 9,093 56.2 122.1 12,694 71.0 139.6 11,382 64.4 89.7 7,443 53.8 65.4

中国 サービス Service 114 0.8 80.9 144 0.9 126.3 196 1.1 136.1 1,084 6.1 553.1 801 5.8 73.9China その他 Others 365 2.5 - 467 2.9 127.9 314 1.8 67.2 732 4.1 233.1 735 5.3 100.4

合計 Total Sales 14,461 100.0 98.0 16,174 100.0 111.8 17,885 100.0 110.6 17,679 100.0 98.8 13,843 100.0 78.3機器 Instrument 1,688 34.6 195.4 1,387 27.3 82.2 1,392 25.9 100.4 1,143 20.0 82.1 1,304 25.6 114.1

ｱｼﾞｱ･ 試薬 Reagent 2,758 56.6 97.2 3,183 62.7 115.4 3,457 64.4 108.6 4,006 70.2 115.9 3,345 65.6 83.5ﾊﾟｼﾌｨｯｸ サービス Service 298 6.1 153.6 307 6.1 103.0 335 6.2 109.1 356 6.2 106.3 299 5.9 84.0Asia- その他 Others 129 2.7 97.0 199 3.9 154.3 185 3.5 93.0 204 3.6 110.3 146 2.9 71.6Pacific 合計 Total Sales 4,875 100.0 121.0 5,078 100.0 104.2 5,370 100.0 105.8 5,710 100.0 106.3 5,096 100.0 89.2

機器 Instrument 19,573 33.1 108.2 18,470 29.9 94.4 16,410 24.9 88.8 16,718 24.4 101.9 16,708 27.6 99.9試薬 Reagent 30,878 52.2 100.9 33,781 54.7 109.4 40,147 60.9 118.8 40,638 59.3 101.2 32,909 54.4 81.0

計 サービス Service 6,656 11.3 92.4 7,260 11.8 109.1 7,598 11.5 104.7 8,660 12.6 114.0 8,624 14.3 99.6Total その他 Others 2,058 3.5 118.0 2,206 3.6 107.2 1,804 2.7 81.8 2,521 3.7 139.7 2,269 3.7 90.0

合計 Total Sales 59,167 100.0 102.6 61,719 100.0 104.3 65,961 100.0 106.9 68,540 100.0 103.9 60,511 100.0 88.3●EMEA︓欧州、中東、アフリカ地域 ●EMEA: Europe, the Middle East and Africa

※1 検査回数に応じて顧客に課⾦する取引について「その他」に含めておりましたが、2016年3⽉期以降「機器」「試薬」「サービス」に分割して表⽰しております。※1 Transactions involving customer billings according to the number of times tests were performed were previously included in “Other Businesses.” However, from the fiscal year ended March 31, 2016, these amounts are divided and presented in “Instrument,” “Reagent” and “Service.”

※2 中国地域において、2016年3⽉期までは消耗品を「試薬」に計上していましたが、2017年3⽉期より「その他」に組み替えております。※2 In China, sales of disposals have been adjusted in "Others" from the fiscal year ended in March 31, 2017 which was formally included in "Reagent."

※3 中国地域において、2019年3⽉期2Qまで「試薬」および「その他」に計上していた⼀部売上を、2019年3⽉期3Qより「サービス」に組み替えております。※3 In China, some sales previously included in “Reagent” and "Others" have been reclassified to “Service” from the third quarter of the fiscal year ended March 31, 2019.

2021.3 1Q決算期 Fiscal Term 2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q※1

※2

※2

※3

※3

12

所在地別売上⾼および営業利益の状況　Net Sales and Operating Income (Loss) by Geographical Region（百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)

決算期 Fiscal Term

所在地 Geographical Region Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y Ratio Y O Y外部売上⾼ Sales to Customers 9,949 29.9 113.5 9,682 27.8 97.3 10,128 30.6 104.6 10,964 32.7 113.2 10,513 31.1 95.9

⽇本 内部売上⾼ Intra-area Transfer 23,332 70.1 112.7 25,088 72.2 107.5 22,937 69.4 91.4 22,520 67.3 89.8 23,313 68.9 103.5Japan 売上⾼ 計 Total Sales 33,282 100.0 112.9 34,770 100.0 104.5 33,066 100.0 95.1 33,484 100.0 96.3 33,826 100.0 101.0

営業利益 Operating Income 10,003 30.1 111.0 9,431 27.1 94.3 8,097 24.5 85.9 6,892 20.6 73.1 6,194 18.3 89.9外部売上⾼ Sales to Customers 12,477 99.3 99.0 13,999 99.3 112.2 13,950 99.6 99.7 14,656 99.5 104.7 12,895 100.0 88.0

⽶州 内部売上⾼ Intra-area Transfer 86 0.7 51.8 91 0.7 105.8 63 0.4 69.2 71 0.5 78.0 1 0.0 1.4Americas 売上⾼ 計 Total Sales 12,564 100.0 98.4 14,091 100.0 112.2 14,013 100.0 99.4 14,727 100.0 104.5 12,896 100.0 87.6

営業利益 Operating Income 575 4.6 123.7 1,657 11.8 288.2 680 4.9 41.1 449 3.0 27.1 △404 △3.1 △90.0外部売上⾼ Sales to Customers 17,436 96.8 99.5 16,803 96.6 96.4 18,704 98.2 111.3 19,591 98.1 116.6 18,231 96.1 93.1内部売上⾼ Intra-area Transfer 576 3.2 282.4 593 3.4 103.0 350 1.8 59.0 379 1.9 63.9 738 3.9 194.7

売上⾼ 計 Total Sales 18,012 100.0 101.6 17,396 100.0 96.6 19,054 100.0 109.5 19,971 100.0 114.8 18,970 100.0 95.0営業利益 Operating Income 1,523 8.5 167.7 1,314 7.6 86.3 1,322 6.9 100.6 1,570 7.9 119.5 1,663 8.8 105.9

外部売上⾼ Sales to Customers 14,458 100.0 98.1 16,166 100.0 111.8 17,851 100.0 110.4 17,658 100.0 109.2 13,809 100.0 78.2中国 内部売上⾼ Intra-area Transfer 1 0.0 100.0 6 0.0 600.0 3 0.0 50.0 0 0.0 0.0 3 0.0 -

China 売上⾼ 計 Total Sales 14,459 100.0 98.1 16,172 100.0 111.8 17,854 100.0 110.4 17,659 100.0 109.2 13,812 100.0 78.2営業利益 Operating Income 790 5.5 45.4 1,849 11.4 234.1 3,476 19.5 188.0 1,839 10.4 99.5 287 2.1 15.6

外部売上⾼ Sales to Customers 4,845 99.8 121.2 5,068 100.0 104.6 5,325 100.0 105.1 5,668 100.0 111.8 5,062 100.0 89.3ｱｼﾞｱ･ﾊﾟｼﾌｨｯｸ 内部売上⾼ Intra-area Transfer 8 0.2 400.0 1 - 12.5 1 0.0 100.0 1 0.0 100.0 1 0.0 100.0Asia-Pacific 売上⾼ 計 Total Sales 4,853 100.0 121.3 5,069 100.0 104.5 5,326 100.0 105.1 5,669 100.0 111.8 5,063 100.0 89.3

営業利益 Operating Income 366 7.6 80.8 452 8.9 123.5 498 9.4 110.2 606 10.7 134.1 284 5.6 46.9外部売上⾼ Sales to Customers 59,167 71.1 102.6 61,719 70.5 104.3 65,961 73.9 106.9 68,540 74.9 111.1 60,511 71.6 88.3

計 内部売上⾼ Intra-area Transfer 24,005 28.9 113.9 25,781 29.5 107.4 23,355 26.1 90.6 22,972 25.1 89.1 24,058 28.4 104.7Total 売上⾼ 計 Total Sales 83,172 100.0 105.7 87,500 100.0 105.2 89,316 100.0 102.1 91,512 100.0 104.6 84,569 100.0 92.4

営業利益 Operating Income 13,259 16.0 105.4 14,705 16.8 110.9 14,075 15.8 95.7 11,358 12.4 77.2 8,025 9.5 70.7消去/ 外部売上⾼ Sales to Customers - - - - - - - - - - - - - - -全社 内部売上⾼ Intra-area Transfer △24,005 - - △25,781 - - △23,355 - - △22,972 - - △24,058 - -

Eliminations/ 売上⾼ 計 Total Sales △24,005 - - △25,781 - - △23,355 - - △22,972 - - △24,058 - -Corporate 営業利益 Operating Income 618 - - △2,273 - - △244 - - △78 - - △1,068 - -

外部売上⾼ Sales to Customers 59,167 100.0 102.6 61,719 100.0 104.3 65,961 100.0 106.9 68,540 100.0 111.1 60,511 100.0 88.3連結 内部売上⾼ Intra-area Transfer - - - - - - - - - - - - - - -

Consolidated 売上⾼ 計 Total Sales 59,167 100.0 102.6 61,719 100.0 104.3 65,961 100.0 106.9 68,540 100.0 111.1 60,511 100.0 88.3営業利益 Operating Income 13,877 23.5 107.8 12,432 20.1 89.6 13,831 21.0 111.3 11,279 16.5 90.7 6,957 11.5 61.7

●EMEA︓欧州、中東、アフリカ地域 ●EMEA: Europe, the Middle East and Africa

※1 ⽇本所在地には、モンゴル、アイデックス社向けなどの売上、利益を含みます。※1 Sales and Operating Income in Japan include those to Mongolia, IDEXX and other countries.

※2 アジア・パシフィック所在地には、モンゴルの売上、利益を含みません。※2 Sales in Asia Pacific exclude Mongolia.

2021.3 1Q

EMEA

2017.3 1Q 2018.3 1Q 2019.3 1Q 2020.3 1Q

※1

※2

13

関連データ　Associated Data

株式情報　Stock Information

　株価推移　Stock Price Range of Sysmex Corporation 　株式の所有者別状況　Composition of Shareholders by Category

※1 2011年4⽉1⽇付︓株式分割（1:2）　※1 Two-for-one stock split conducted on April 1, 2011※2 2014年4⽉1⽇付︓株式分割（1:2）　※2 Two-for-one stock split conducted on April 1, 2014

　出来⾼　Trading Volume of Sysmex Corporation 　株主数の推移　 　発⾏済株式数の推移 Number of Shareholders  Number of Shares Issued

0

2,000

4,000

6,000

8,000

10,000

12,000

'10/6 '10/12 '11/6 '11/12 '12/6 '12/12 '13/6 '13/12 '14/6 '14/12 '15/6 '15/12 '16/6 '16/12 '17/6 '17/12 '18/6 '18/12 '19/6 '19/12 '20/6

※2

0

500

1000

1500

2000

2500

3000

'10/6 '10/12 '11/6 '11/12 '12/6 '12/12 '13/6 '13/12 '14/6 '14/12 '15/6 '15/12 '16/6 '16/12 '17/6 '17/12 '18/6 '18/12 '19/6 '19/12 '20/6

(万株) (10 thousand shares)

■ ⾦融機関Financial Institutions

■ ⾦融商品取引業者Financial Instruments Firm

■ その他国内法⼈Other JapaneseCompanies

■ 外国法⼈等Foreign Investors

■ 個⼈、その他Individuals and Others

（） 株式数Number of shares

<> 保有者数Number of shereholders

(円) (JPY)

14,47214,984

11,954

16,261

14,862

'16.3 '17.3 18.3 '19.3 '20.3

208,332 208,631 208,964 209,154 209,266

'16.3 '17.3 18.3 '19.3 '20.3

(千株)(thousand shares)

※1

20.79%(43,479,816)<81>

19.91%(41,657,055)<145>

41.56%(87,001,743)<776>

17.04%(35,658,873)<13,824>

0.70%(1,468,945)<36>

(2020年3⽉31⽇現在)

(As of March 31, 2020)

14

会社概要　Corporate Data

シスメックス株式会社Sysmex Corporation

本社所在地 〒651-0073 兵庫県神⼾市中央区脇浜海岸通1丁⽬5番1号Address of Head Office 1-5-1, Wakinohama-Kaigandori, Chuo-ku,Kobe, Hyogo 651-0073, Japan

電話番号／Telephone (078)265-0500（代表）

FAX／Facsimile (078)265-0524

設⽴年⽉⽇／Date of Establishment 1968年2⽉20⽇／February 20,1968

資本⾦（千円）／Paid-in Capital (JPY thousand) 12,965,399

従業員数 ※嘱託及びパートタイマーなどを含む／Number of Employees ※Including part-time employee

単独（名）／Non-Consolidated 2,727

連結（名）／Consolidated 9,385

従業員平均年齢（才）／average age 40.8

従業員平均勤続年数（年）／average years of employment 12

発⾏済株式総数（千株）／Number of Shares Issued(thousand shares) 209,310

決算期／Settlement Day 3⽉31⽇／March 31

上場市場／Stock Listings 東京証券取引所市場第⼀部／Tokyo Stock Exchange, First Section

証券コード／Stock Exchange Code Number 6869

主な事業内容 臨床検査機器、検査⽤試薬ならびに関連ソフトウェアなどの開発・製造・販売・輸出⼊Main Line of Business Development,manufacture, sales, import and export of diagnostics testing instruments and reagents, and related software

主な販売先 国⽴病院、⼀般病院、⼤学、研究所、その他医療機関Customers National and public hospitals, general hospitals, and other medical institutions, universities, and research institutes

(2020年6⽉30⽇現在)

(As of June 30, 2020)

15

Printed in Japan1‐5‐1 Wakinohama‐Kaigandori, Chuo‐ku, Kobe 651‐0073, JapanTel. +81 (78) 265‐0500  Fax. +81 (78) 265‐0524